Heparin inhibits intracellular *Mycobacterium tuberculosis* bacterial replication by reducing iron levels in human macrophages

Rodrigo Abreu1, Lauren Essler1,2, Allyson Loy1,2, Frederick Quinn1 & Pramod Giri1

Iron is a crucial micronutrient for both mammals and their associated pathogens, and extensive literature has shown that *Mycobacterium tuberculosis* (Mtb) bacilli inhibited from acquiring iron from the host are severely attenuated. In contrast, increased dietary iron concentrations or patients with hemochromatosis have long been associated with a more severe tuberculosis (TB) disease outcome. We have observed that upon macrophage infection, Mtb bacilli strongly promote intracellular iron sequestration, both through increased expression of hepcidin, a key mammalian iron regulatory protein, and downregulation of the iron exporter protein, ferroportin. Heparin is a highly sulfated glycosaminoglycan released by mast cells and basophils at sites of tissue injury. During Mtb infection, heparin alters intracellular trafficking in alveolar epithelial cells and decreases extrapulmonary dissemination but recently, heparin also has been reported to inhibit hepcidin expression in hepatocytes, decreasing intracellular iron availability. In this report, we demonstrate that heparin significantly reduces hepcidin expression in macrophages infected with Mtb bacilli. Heparin-treated macrophages have higher ferroportin expression compared to untreated macrophages, promoting iron export and decreasing iron availability to intracellular bacilli. Thus, here we describe a novel immunomodulatory effect and potential therapeutic role for heparin against mycobacterial infection in human macrophages.

*Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB), infects nearly 10 million people annually and causes approximately 1.5 million fatalities globally. Despite extensive efforts to control and eradicate TB, we are still failing to meet the milestones of the WHO *End TB strategy*. One-third of the world population is estimated to be latently infected with Mtb with a 10% lifetime risk of reactivation. However, for immunocompromised patients the risk increases to a 10% chance of disease progression every year1.

*Mycobacterium tuberculosis* is one of the most prevalent human pathogens that has evolved to persist in alveolar macrophages ultimately causing extensive lung inflammation and pathology2,3. Macrophages serve as the major intracellular niche for Mtb. Upon successful infection, Mtb bacilli evade the macrophage innate antimicrobial functions, inhibit the phagolysosome fusion process and gain access to crucial intracellular nutrients4. Inhibition of the inflammasome and impaired IL-1β secretion is associated with increased intracellular bacterial proliferation5. Alternatively, chelation of intracellular nutrients such as iron strongly inhibits Mtb replication in macrophages6,7. Iron dysregulation has been strongly associated with worsened disease outcomes in Mtb infected patients8, while effective iron export in macrophages decreased intracellular mycobacterial replication8.

Heparin is a highly sulfated glycosaminoglycan released by mast cells and basophils at sites of tissue injury. Despite its well-described anticoagulant activity, heparin’s physiological role in innate immunity during infection is not fully understood9. The mycobacterial adhesin heparin-binding hemagglutinin (HBHA) is an important virulence factor for adhesion, internalization and dissemination from the lung during Mtb infection10,11. Heparin and other glycosaminoglycans can decrease the Mtb bacterial burden in epithelial cells, but its impact in intracellular replication in macrophages has not yet been investigated. Heparin has multiple modulatory effects on the host cells11. For example, heparin has been implicated in multiple biological processes and is capable of...
interacting with hundreds of human proteins\textsuperscript{14,15}. As an immunomodulatory molecule, heparin has been shown to inhibit complement activation, modify cytokine secretion in human mononuclear cells and inhibit leukocyte recruitment\textsuperscript{16–19}. Heparin also has been reported to have some antiviral activity through direct interaction with viral proteins\textsuperscript{20,21}.

Most studies with heparin have been performed on hepatocytes, where the glycosaminoglycan has been shown to inhibit hepcidin expression, thereby decreasing intracellular iron levels in this iron regulatory cell type\textsuperscript{22–25}. Interestingly, we have now observed that upon macrophage infection, \textit{Mtb} bacilli strongly promote intracellular iron sequestration both through induction of hepcidin and direct down-regulation of the iron exporter ferroportin (unpublished data).

In this study, we report that heparin significantly inhibits hepcidin expression in human macrophages after mycobacterial infection. Heparin-treated macrophages express higher ferroportin surface levels compared to untreated controls, promoting iron export and decreasing iron availability to intracellular bacilli. Similar to iron-chelation treatment, heparin significantly reduces \textit{Mtb} intracellular replication in macrophages. Bacterial internalization and intracellular viability rates were similar between the heparin-treated and control infections, thus the observed lower replication rate is likely the result of the inability of the intracellular bacilli to sequester iron from their niche.

This study suggests a new immunomodulatory function of heparin in macrophages, and a possible protective mechanism for sulfated glycosaminoglycan during \textit{Mtb} infection. The outcome of this study also provides impetus for screening and assess of modified heparins as novel immunomodulatory anti-mycobacterial therapeutic molecules.

**Results**

**Heparin decreases mycobacterial intracellular replication in human macrophages.** Heparin-binding hemaglutinin protein (HBHA) may be an important adhesin for effective attachment of \textit{Mtb} bacilli to alveolar epithelial cells\textsuperscript{11}. However, other than binding to HBHA and interfering with attachment to these epithelial cells, the roles for heparin and other sulfated glycosaminoglycans in \textit{Mtb} intracellular replication and survival have not been tested. \textit{Mycobacterium bovis} BCG is an avirulent vaccine strain frequently used as a BSL2 model to study \textit{Mtb} replication in macrophages. To assess the impact of heparin on \textit{Mtb} internalization and intracellular replication, \textit{THP-1} macrophages were treated overnight with 50 \( \mu \)g/ml (\( \approx 10U/ml \)) heparin and infected with opsonized BCG at a MOI of 10. After two hours, bacterial uptake was similar between the heparin-treated and untreated macrophages (\( p = 0.792 \)); however, by 24 hours post infection, heparin-treated macrophages showed a significant 50.6\% (\textpm 6.97\%) reduction in intracellular bacterial numbers when compared to untreated controls (\( p = 0.006, \text{Fig. 1A and B} \)). Because BCG is an avirulent strain of \textit{M. bovis}, intracellular replication is limited compared to fully virulent strains in human macrophages. Thus, after 48 hours, intracellular replication stops for control BCG infections, unrelated to the heparin treatment (Fig. 1B).
Considering the reduction in early intracellular BCG replication, we assessed and compared the impact of heparin treatment on Mtb-infected macrophages. As observed with BCG, heparin-treated and control macrophages showed no differences in Mtb uptake two hours after internalization ($p = 0.556$, Fig. 1C). However, by 48 hours post infection, heparin-treated macrophages showed significantly decreased intracellular bacterial burdens compared to untreated controls ($p = 0.045$, Fig. 1C and D). By 72 hours post infection, heparin treatment continued to decrease the intracellular bacterial burden compared with untreated controls, reaching a 64% ($\pm 5.807$) decrease (Fig. 1D). Furthermore, heparin treatment significantly improved macrophage cell viability by 72 hours after Mtb infection (mean difference was $28 \pm 4.082\%$, Fig. 1E). Altogether, these data point to a host-protective role of heparin during Mtb infection by limiting intracellular bacterial burden in macrophages.

Heparin treatment does not affect bacterial viability in vitro. Heparin antimicrobial activity against Gram-positive bacteria has been long reported\(^{26}\), but its impact on the growth of *Mycobacterium* species has not been evaluated. When 7H9 medium was supplemented with 50 $\mu$g/ml of heparin, replication rates were not affected as measured by changes in absorbance patterns (OD$_{600}$) (Fig. 2A). Since the effects could be exacerbated in a hostile environment such as within macrophages, increasing heparin concentrations (up to 250 $\mu$g/ml) in 7H9 medium also was assessed, but no changes in BCG growth were observed compared to untreated broth (Fig. 2B).

Heparin interacts with a myriad of serum proteins including complement factors\(^{15}\). During infection, heparin was added to complete RPMI medium with heat inactivated FBS. To evaluate if heparin is promoting Mtb killing through interaction with serum-proteins, $2.5 \times 10^6$ bacilli were incubated in heparin containing C-RPMI for 72 hours in the absence of macrophages. Aliquots were spread onto 7H10 agar plates, and viable counts assessed. Again, heparin showed no direct bactericidal activity in C-RPMI medium ($p = 0.216$, Fig. S1B).

Altogether, these data demonstrate that heparin decreases Mtb replication through an indirect mechanism dependent on intracellular macrophage activity.

Heparin treatment does not affect bacterial internalization. Heparin treatment has no impact on overall viable bacterial uptake compared to untreated control cells (Fig. 1A and C). However, the impact of heparin treatment on the percentage of host cells infected also was assessed. In these studies, heparin-treated macrophages were infected with red-fluorescent protein (RFP) labeled BCG and the percentage of infected cells

---

**Figure 2.** Heparin has no direct impact in bacterial growth or macrophage internalization. (A,B) BCG (A) and Mtb (B) growth in heparin-supplemented 7H9 medium. (C) Percentage of infected cells in 9 random fields (10x) from 3 independent experiments as represented in (B). (D) BCG expressing RFP in THP-1 infected macrophages treated overnight with 50 $\mu$g/ml heparin two hours after internalization. Data from three independent experiments.
was quantified by fluorescence microscopy two hours after internalization (Fig. 2D). In agreement with the total uptake results, heparin-treatment had no impact on the percentage of infected macrophages (p = 0.3) (Fig. 2C).

These data indicate that heparin’s impact on the intracellular mycobacterial burden is independent of its previously reported role in bacterial attachment and dissemination11.

Heparin induces IL-1β secretion during Mtb infection. IL-1β has been well correlated with a protective response to Mtb infection, thus the secretion of this cytokine was assessed in heparin-treated macrophages5. Heparin treatment alone does not induce IL-1β secretion in macrophages, although, 24 hours after Mtb or BCG infection, heparin-treated macrophages secrete significantly more IL-1β compared to untreated controls (mean difference was 38.38 ± 2.443 pg/ml, Fig. 3A). Infection with Mtb bacilli is known to induce IL-1β both through inflammasome- (NLRP3) dependent and independent pathways27. Thus, the contribution of heparin towards the induction of IL-1β was assessed after stimulation with NLRP3 specific ligands such as nigericin and ATP. Despite a marginally significant increase in IL-1β secretion by heparin-treated macrophages after LPS and nigericin treatment (mean difference was 12.79 ± 3.054 pg/ml, p = 0.014, Fig. S2A), Mtb infection generated a more robust response (mean difference was 529.90 ± 11.16 pg/ml, Fig. 3A). In contrast, ATP-induced IL-1β is not affected by heparin treatment (p = 0.181, Fig. S2A), and heparin could not act as a sole first or second signal for inflammasome activation (Fig. S2B).

To confirm that heparin’s protective role during Mtb infection was dependent on IL-1β secretion, the impact of heparin treatment using caspase recruitment domain- (ASC)-deficient THP-1 (THP-1 ASC def) macrophages was assessed during Mtb infection. THP-1 ASC def macrophages have impaired inflammasome activation and decreased IL-1β secretion after Mtb infection (Fig. 3B). In accordance with the previously reported protective effect of IL-1β, ΔASC-THP-1 macrophages showed increased intracellular bacterial replication compared to parent THP-1 cells (p = 0.013, Fig. 3C). Surprisingly, after heparin treatment, THP-1 ASC def macrophages still showed a decreased intracellular bacterial burden at 48 and 72 hours post infection compared to untreated cells. In fact, when normalized to the respective untreated controls (Fig. 3E), THP-1 ASC def heparin-treated macrophages supported increased bacterial replication in relation to parent heparin-treated cells at 24 hours (p = 0.015), but by 48 and 72 hours post infection, intracellular bacterial replication was inhibited to similar levels in both cell lines (p = 0.93, Fig. 3E). These data suggest that heparin-induced IL-1β secretion is not responsible for the major differences in bacterial burden observed at later time points (48–72 hours) in our infection model.

Heparin inhibits hepcidin expression in THP-1 macrophages. Heparin is a known inhibitor of hepcidin expression in hepatocytes22 and hepcidin has been associated with increased replication of intracellular pathogens28,29. To test if heparin can inhibit hepcidin expression in macrophages, THP-1 macrophages were treated with 50µg/ml heparin overnight and hepcidin mRNA expression was measured by qRT-PCR.
TLR4 activation induces hepcidin expression in macrophages\(^{30,31}\). To see if heparin could inhibit TLR-mediated hepcidin induction, heparin-treated macrophages were stimulated with LPS (500 ng/ml) for 24 hours and hepcidin gene transcription was assessed by qRT-PCR. These data were in accordance with a previous report that showed LPS treatment induces hepcidin expression in macrophages (13.61 ± 3.76 fold), however this response was not significantly affected by the addition of heparin (\( p = 0.3406 \), Fig. S3A).

We previously observed that iron supplementation greatly enhances TLR4-mediated hepcidin expression (unpublished data), thus the ability of heparin to inhibit hepcidin expression was assessed under these conditions (Fig. S3B). When grown in FeAC supplemented medium, LPS-stimulated macrophages showed a 39.78-fold (±3.53) induction in hepcidin mRNA levels compared to controls (\( p < 0.001 \)); however, heparin-treated macrophages expressed significantly less hepcidin expression when stimulated under the same conditions (mean difference was 35.68 ± 3.56). In fact, LPS-mediated hepcidin induction is lower in heparin-treated macrophages grown in iron-supplemented versus iron-free media (Fig. S3B).

BCG and Mtb activate TLR4 signaling, and have been shown to induce hepcidin in iron-supplemented medium (unpublished data). Thus, the inhibition of BCG-induced hepcidin expression in THP-1 macrophages also was assessed. After BCG infection, heparin-treated macrophages showed decreased hepcidin mRNA levels compared to untreated controls (mean difference was 28.72 ± 2.32 fold, Figs 4A,B and S5). Consistently, hepcidin secretion is decreased four-fold in the culture supernatants from heparin-treated macrophages after BCG (Fig. 4D) and Mtb infection (Fig. 4D,E).

Overall, these results show that heparin inhibits Mtb-induced hepcidin expression in macrophages.

**Heparin inhibits hepcidin-mediated ferroportin internalization and degradation.** Secreted hepcidin binds to the iron exporter protein ferroportin, leading to its internalization and degradation\(^{32}\). Heparin can prevent LPS-mediated hepcidin expression and consequent ferroportin internalization in macrophages (Fig. S4). Like LPS treatment, BCG infection leads to decreased surface ferroportin levels 48 hours after infection, which overlaps with maximum differences in hepcidin expression (Fig. S4A). Quantification of mean pixel fluorescence intensity shows that infected cells express 44% less ferroportin and 16 times more hepcidin than uninfected controls (Fig. 5B). Interestingly, 48 hours after infection, 75.8 ± 0.02% of intracellular BCG bacilli in macrophages would co-localize with ferroportin, although in heparin-treated macrophages only 43 ± 0.5% of BCG bacilli overlap with ferroportin staining (Figs 5C and S6). This shows that heparin inhibits hepcidin-mediated ferroportin internalization and degradation.

**Heparin decreases intracellular iron levels.** Increased intracellular iron is normally associated with increased ferritin expression. Similarly, increased hepcidin secretion and decreased ferroportin expression are associated with increased intracellular iron sequestration. Macrophages infected with BCG express higher ferritin levels than uninfected controls, also suggesting increased intracellular iron sequestration (Figs 6A and S7A and B).
Heparin treatment can slightly decrease ferritin expression after BCG infection but not to levels that resemble uninfected cells (Figs 6A and S7A and B).

*Mycobacterium tuberculosis* and BCG can sequester iron from cytoplasmic iron storage compartments of infected macrophages. In this study, intracellular ferritin distribution was assessed after BCG infection. Consistent with western blot data, BCG-infected macrophages have higher levels of ferritin compared to uninfected controls.

**Figure 5.** Heparin-treated macrophages have increased ferroportin levels. (A) Ferroportin expression in heparin-treated macrophages 48 hours after BCG infection (63X). (B) Ferroportin expression in heparin-treated macrophages 48 hours after BCG infection, measured as Pixel MFI/cell from a minimum of 20 cells in three different fields (40X) from three independent experiments. (C) Percentage of BCG bacilli colocalized with ferroportin-FITC staining (overlapping red and green pixels). Data from three independent experiments. **p < 0.01, ***p < 0.001.

**Figure 6.** Heparin decreases iron availability to intracellular mycobacterial bacilli. (A) Ferritin expression in heparin-treated macrophages 48 hours after BCG infection. (B) Percentage of ferritin-positive BCG bacilli in five fields from three independent experiments as represented in (A). (C) Nuclear ferritin in heparin-treated macrophages 48 hours after BCG infection measured by percent of double-positive pixels (FITC and DAPI). (D) Total intracellular iron staining (Prussian blue) in heparin-treated macrophages 48 hours after BCG infection. Data from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.

Heparin treatment can slightly decrease ferritin expression after BCG infection but not to levels that resemble uninfected cells (Figs 6A and S7A and B).

*Mycobacterium tuberculosis* and BCG can sequester iron from cytoplasmic iron storage compartments of infected macrophages. In this study, intracellular ferritin distribution was assessed after BCG infection. Consistent with western blot data, BCG-infected macrophages have higher levels of ferritin compared to uninfected controls.
resulting from increased intracellular iron sequestration (Fig. 6A). Surprisingly, in uninfected macrophages ferritin localizes to the nucleus, with very little distribution in the cytoplasm. Upon BCG infection, ferritin is found in the cytoplasm (Fig. 6C). This can be confirmed microscopically by strong association between infecting bacilli and labeled ferritin (87.6 ± 1.7% ferritin-positive intracellular bacilli, Fig. 6B). Heparin has no impact on intracellular ferritin levels in BCG infected macrophages, but it seems to alter its intracellular distribution with increased nuclear localization (Fig. 6C) and decreased association with the BCG bacilli (31.1 ± 2.1%, Fig. 6B).

Decreased ferritin without increased iron export leads to increased free iron levels which have a complex role in bacterial survival and replication. Free cytoplasmic iron is easily accessible by the intracellular bacteria, but if the iron is transported to the phagolysosome, it contributes to reactive oxygen species production through the Fenton reaction which strongly promotes bacterial killing. To evaluate the impact of heparin treatment on the intracellular labile iron pool (LIP), the percentage of calcine fluorescence quenching in heparin-treated macrophages was assessed after LPS stimulation. LPS treatment mimics some aspects of BCG or Mtb infection with strong hepcidin and ferritin induction, ferroportin down regulation and increased intracellular iron levels (Fig. S7D). Iron supplementation promotes a moderate but significant increase in the intracellular LIP, however, this is not altered by LPS stimulation until six hours after treatment. After 24 or 48 hours post treatment, LPS-treated cells have much higher intracellular LIP levels, as observed by increased calcine–quenching (67.1% decrease in fluorescence). Nonetheless, LPS-induced LIP is not changed in heparin-treated macrophages suggesting that heparin does not alter intracellular LIP levels. Pam3CSK4, the TLR2/TLR4 activator, induces intracellular iron arrest by direct transcriptional down regulation of ferroportin and through a hepcidin-independent mechanism (unpublished data). Pam3CSK4-treated macrophages show similar intracellular LIP with LPS-treated cells, suggesting regulation of LIP in macrophages is independent of hepcidin expression.

Ferritin expression is strongly associated with iron storage levels, but does not represent total iron content of the cell; total intracellular iron levels can be assessed by Prussian blue (PB) staining. Consistent with our previous observations, uninfected macrophages have low iron content, as seen by low staining (Fig. 6D). However, upon BCG-infection, intracellular iron content is increased (12.7 ± 5.1%). In contrast, heparin-treated infected macrophages show significantly decreased intracellular iron levels compared to uninfected controls (p = 0.01) and untreated infected cells (p = 0.007) (Figs 6D and S7C). Overall, these results demonstrate that heparin decreases iron availability to intracellular mycobacteria in macrophages.

Heparin can only inhibit intracellular BCG and Mtb replication under high intracellular iron conditions. Mycobacterium bovis BCG replication is generally well contained in human macrophages, although virulence can be promoted by different mechanisms. Iron supplementation promotes enhanced BCG replication in macrophages which can be inhibited by heparin treatment (Fig. 7B). Furthermore, it has been shown previously that BCG can only induce hepcidin expression in macrophages when grown in iron-supplemented medium (Fig. 7A), thus, the impact of heparin treatment was assessed in non-iron-supplemented medium. When compared to untreated controls, heparin treatment had no impact on intracellular bacterial replication in plain RPMI (no iron added) (Fig. 7B), further connecting heparin with hepcidin down regulation and decreased iron availability.

Deferiprone is an iron chelator clinically approved for the treatment of iron overload disorders and thalassemia. During Mtb infection, treatment with deferiprone significantly decreases intracellular bacterial replication in macrophages (Fig. 7C). In agreement with heparin’s impact in iron availability to intracellular bacilli, heparin/deferiprone-treated macrophages have similar bacterial burdens to deferiprone-alone treated controls (Fig. 7C).

Hepcidin supplementation increases intracellular bacilli replication in heparin-treated macrophages. Hepcidin25 synthetic peptide is commercially available and has been shown to maintain the iron modulatory function of the native protein. To prove that heparin-mediated hepcidin inhibition is responsible for decreased intracellular bacterial burden at later time points of infection, heparin-treated macrophages were supplemented with hepcidin25 synthetic peptide. As predicted, hepcidin supplementation rescued intracellular bacterial replication in heparin-treated macrophages; however, no significant increase in untreated macrophages was detected (Fig. 7D).

Discussion

Notwithstanding the efforts to eradicate it, tuberculosis has again become the leading cause of death due to an infectious disease. The increase in infections with multidrug-resistant and extensively-drug resistant strains makes the use of therapeutics as our only effective intervention strategy a unsustainable plan. Thus, a truly effective control strategy requires that new therapeutics and a more effective vaccines are developed. In this report a protective immunomodulatory role for heparin during Mtb infection in macrophages is described. We demonstrate that heparin modulates macrophage iron status, and decreases iron availability for intracellular bacilli, thus limiting bacterial replication.

Mycobacterium tuberculosis bacilli persist and reside inside alveolar macrophages. To replicate within the phagosome of these cells, Mtb bacilli must recruit essential nutrients, such as iron to this vesicular compartment. Despite the important role of macrophages in iron recycling from erythrophagocytosis, free iron is extremely scarce inside the macrophage being rapidly redistributed extracellularly through the iron exporter ferroportin or sequestered by the iron storage protein ferritin.

Mycobacterium tuberculosis bacilli possess a myriad of mechanisms for iron scavenging inside the host. For example, PAMPs activate TLR2 and TLR4 signaling and promote intracellular iron sequestration in macrophages through induction of hepcidin and down regulation of ferroportin (unpublished data). In addition, increased expression of mycobactin and carboxymycobactin siderophores efficiently recruit and scavenge iron for use by the intracellular mycobacteria within the phagosome. Carboxymycobactin is the major iron-chelator for both...
free and protein-bound iron in the macrophage phagosome and cytoplasm,
while surface mycobactin acts as a membrane chelator and iron-transporter recovering iron from carboxymycobactin and host ferritin. Both molecules are essential for iron acquisition and pathogenesis as shown by the severe attenuation of Mtb knock-out strains with impaired siderophore synthesis.

In this study, heparin treatment significantly inhibited Mtb-mediated hepcidin secretion (Fig. 4) culminating in increased ferroportin expression 48 hours after infection (Fig. 5). Poli et al. have previously shown that heparin can inhibit hepcidin expression in hepatocytes, but it is shown here that this highly sulfated glycosaminoglycan has a similar impact in TRL-mediated hepcidin expression in myeloid cells.

Mycobacterium tuberculosis infection promotes increased intracellular iron sequestration and ferritin expression (Fig. 6). Luo et al. showed that Mycobacterium paratuberculosis mycobactin J (mbtJ) rapidly disperses from the phagosome in host lipid cellular components, accessing the macrophage intracellular iron pool. Iron loaded mbtJ localizes with lipid droplets that are later associated with the phagosome. Here, heparin had no impact in the intracellular labile iron pool (Fig. S7), but greatly decreased total intracellular iron levels, potentially protein-bound (Fig. 6D). In macrophages, ferritin mostly localizes to the nucleus with minimal cytoplasmic distribution (Fig. 6). Ferritin nuclear translocation has been previously reported in murine macrophages during iron overload, but its mechanism and function remain unclear. Macrophages infected with BCG bacilli have decreased ferritin nuclear co-localization, despite the increase in ferritin expression (Fig. 6A), while heparin-treated macrophages show a nuclear ferritin distribution comparable to uninfected cells. Interestingly, heparin also decreases ferritin-BCG co-localization further decreasing iron availability for the intracellular bacilli (Fig. 6).

Decreased intracellular iron availability through chelation therapy significantly limits intracellular mycobacterial growth and Fig. 7). In our study, heparin impacts intracellular BCG replication in the presence of iron and can be counteracted by the addition of hepcidin to the medium (Fig. 7), indicating that heparin-mediated hepcidin inhibition and the decrease in intracellular iron availability are the major action mechanisms limiting intracellular replication. De facto, a similar mechanism has been described in IFN-γ-activated murine macrophages. In that report, IFN-γ-induced ferroportin expression contributed to efficient control of Salmonella enterica intracellular replication.

Alveolar macrophages and potentially type II pneumocytes are the primary cell targets during Mtb infection. Heparin is known to prevent mycobacterial attachment to and internalization of type II pneumocytes. However, macrophages actively phagocyte opsonized bacteria through Fcγ receptors and the complement receptor. In this study, heparin treatment of macrophages had no impact on bacterial attachment and internalization, but intracellular replication was reduced at later time points compared to untreated controls. Phagocytosis of...
opsonized Mtb bacilli by resident macrophages in the lung leads to phagosome acidification and lysosome fusion, increased reactive oxygen and nitrogen species, and recruitment of antibacterial peptides culminating in bacterial clearance. Nonetheless, Mtb bacilli activate an arsenal of virulence factors which block efficient macrophage antibacterial functions. An example of these Mtb blocking factors include secretion of phosphotyrosine protein phosphatase (Ptpa) immediately upon Mtb macrophage internalization. This protein inhibits host membrane fusion proteins and host V-ATPases required for phagosome maturation and acidification. An additional factor is Mtb nucleoside diphosphate kinase (NdK) which inhibits phagolysosome fusion and NOX2-mediated ROS production. It would be interesting to determine if heparin can counteract bacterial factors and impact early events after phagocytosis such as phagosome maturation, lysosome fusion and promote efficient bacterial killing. The use of porcine unfractionated heparin (UFH) raises limitations to direct translation from our study into a novel therapeutic strategy. UFH is a mixture of heparins of variable sizes with limited bioavailability and extremely variable anticoagulant pharmacological properties. Still, over the last decade extensive efforts have been made to develop modified heparins with improved and more targeted pharmacological activities. Recently, Poli et al. revealed that glycol-split non-anticoagulant heparin fractions can mimic intracellular signaling of UFH leading to hepcidin inhibition in hepatocytes. Future studies will examine if these non-anticoagulant heparins can prevent Mtb-mediated iron sequestration in macrophages and limit intracellular bacterial replication while limiting side effects.

Iron dysregulation has been long associated with increased risk of developing TB. Moreover, hepcidin serum levels are strongly correlated with Mtb– HIV co-infection. Heparin expression and decreased iron export have been shown to increase HIV replication rates in macrophages, reinforcing the importance of this hormone in co-infection. This study leads the way towards a potential use of hepcidin inhibitors such as heparin, as an efficient therapeutic strategy against TB, and a promising prospect for immunomodulatory therapies in HIV-Mtb co-infected patients.

Methods

Cell culture and macrophage differentiation. The THP-1 monocytic cell line was obtained from ATCC (TIB-202), maintained in complete RPMI with 2 mM glutamine and supplemented with 10% fetal bovine serum (C-RPMI). For differentiation into a macrophage-like phenotype, 8 × 10⁷ cells/ml were treated with 50 nM phorbol 12-myristate 13-acetate for 24 hours and rested overnight in C-RPMI with 100 µM ferric ammonium citrate (FeAC). When stated, 50 µg/ml heparin (≈10U/ml) was subsequently added to the medium during overnight resting. THP-1 cells deficient in PYD, the CARD Domain Containing (THP-1 ASCΔcef) cells and the parent strain, all were obtained from Invivogen (CA USA), and maintained and differentiated as described above for the ATCC THP-1 original cell line.

Bacterial strains and infection. The strains used in this study were Mycobacterium bovis BCG Pasteur, and Mtb Erdman generously provided by Dr Jeff. Cox (UC Berkeley, CA USA). Strain BCG Pasteur expressing RFP was generously provided by Dr. Andrew Mellor (Augusta University, GA, USA). Bacteria were grown to an OD₆₀₀ ≈ 0.8 in 7H9 medium supplemented with ADC, 5% glycerol and 0.5% Tween 80, and aliquots frozen at −80°C. Frozen aliquots were thawed, serially diluted and plated on 7H10 agar medium containing 10% ADC for three weeks at 37°C. Viability was measured as colony forming units/ml (CFU/ml). Prior to infection, BCG or Mtb bacilli were passed through a 21G tuberculin syringe and opsonized for 2 hours in RPMI with 10% non-heat inactivated horse serum at 37°C with gentle rocking.

For infection, 1.5 × 10⁸, 3 × 10⁸ or 8 × 10⁸ PMN-differentiated THP-1 macrophages were incubated in C-RPMI with opsonized bacteria in 12, 48 or 96 well plates respectively at a multiplicity of infection of five to ten bacilli per host cell for two hours at 37°C with 5% CO₂. After internalization, macrophages were washed three times with warm PBS. After washing, C-RPMI containing 50 µg/ml gentamicin and 50 µg/ml heparin was added to the infected cells and maintained throughout the experiment. For intracellular bacterial burden quantification, cells were lysed at indicated time points with 0.1% TritonX-100 for 10 minutes and serial dilutions plated on 7H10 agar medium containing 10% ADC. CFUs were counted twice after incubation for 19 to 23 days at 37°C.

Heparin bacteriostatic and bactericidal assay. BCG bacilli were grown in complete 7H9 medium with increasing heparin concentrations (50 to 250 µg/ml), in T25 flasks, at a starting OD₆₀₀ ≈ 0.001. Growth was measured daily by changes in OD₆₀₀ of 100 µl aliquots in 96 well flat bottom plates and assayed using Powerwave XS2 (Biotek, VT USA).

Mtb Erdman bacilli were grown similarly to BCG, but changes in absorbance were measure in 13 mm diameter spec tubes and essayed using a Spectronic 20+ spectrophotometer.

To assay heparin bactericidal activity, 2.5 × 10⁸ bacteria were incubated in C-RPMI with 50 µg/ml heparin for 72 hours at 37°C with 5% CO₂, and serial dilutions plated on 7H10 agar medium containing 10% ADC. CFUs were counted twice after incubation for 19 to 23 days at 37°C.

RNA extraction and real-time PCR. Total cellular RNA from 1 × 10⁶ THP-1 macrophages was extracted using TRizol (Invitrogen, Thermo Fisher Scientific, MA USA) following the manufacturer’s protocol and reverse transcribed into cDNA using SuperscriptIII First strand cDNA synthesis Kit (Invitrogen) with poly dT20 primers. Quantitative PCR (qPCR) was performed using Bio-Rad IQ SYBR green supermix (Bio-Rad, CA USA) in a iQ™5 Real-Time PCR Detection System. All values were normalized against GAPDH (∆∆CT = CT [HAMP] – CT [GAPDH]). Fold change in expression was calculated as 2−∆∆CT, where ∆∆CT = ∆CT (test sample) − ∆CT (control). The primer sequences for the genes examined were the following: human Hamp, forward, 5′-GGATGCCCATGTTCCAGAG-3′; reverse, 5′-AGGACATCCCACTCCTTTGAT-3′; human GAPDH, forward, 5′-GGCATCCAGGACCTTGTG-3′; reverse, 5′-TGTTGTCACGGTTCCTTAC-3′.
Hepcidin secretion quantification.  Hepcidin levels in culture supernatants were determined using the human hepcidin DuoSet Elisa Kit (R&D Systems, MN USA), per manufacturer’s recommendations.

Protein extraction and Western blot analysis.  For western blot, 1 × 10⁶ cells were cultured in 6-well plates, washed twice with ice-cold PBS and lysed with ice-cold IP lysis for 30 minutes on ice. Cell lysates were further disrupted manually by vigorous pipetting and vortexing. After centrifugation (10,000 × g) for 15 minutes at 4°C, supernatants were collected and stored at –20°C until analyzed.

Total protein content was determined by using the BCA protein estimation assay kit (Pierce, Thermo Fisher Scientific MA USA). Samples (20µg) were mixed with Laemmli buffer (1x final concentration), heated at 70°C for 10 minutes, and proteins were electrophoretically separated on a 15% sodium dodecyl sulfate (SDS)–polyacrylamide gel. The proteins were transferred to a PVDF membrane (Bio-RAD), which was then pre-incubated with blocking solution (5% nonfat dry milk in Tris-buffered saline containing 0.01% Tween20 [TBST], pH 7.4) for one hour, followed by overnight incubation with 1µg of anti-FTH1 (ferritin) rabbit monoclonal antibody (Cell signaling Tech., MA USA) and 1µg Anti-GAPDH rabbit monoclonal antibody (cell signaling) at 4°C. After primary incubation, the membrane was washed 3x with TBST and incubated for one hour with secondary anti-rabbit HRP conjugated antibody (Cell signaling Tech).

All incubations and wash steps were performed at room temperature except when otherwise stated. Cross-reactivity was visualized by using enhanced chemiluminescence (SuperSignalWestPico; Pierce).

Immunofluorescence microscopy.  Anti-ferroportin and anti-hepcidin antibodies for ferroportin and hepcidin detection were kindly provided by Dr. Tara Arvedson, and immunofluorescence staining was done as previously described. Briefly, 2 × 10⁶ THP-1 macrophages were grown and differentiated in eight or 16 well chamber microscop-cy slides and infected as described above, fixed with 4% PFA overnight and permeabilized with 0.1% Triton X-100. For ferroportin staining, cells were incubated with 2µg/ml mouse antibody diluted in C-RPMI overnight. For detection, cells were incubated with 2µg/ml goat anti-mouse alexa-fluor-488 (Invitrogen, Thermo Fisher Scientific. MA USA) at 4°C for two hours. Cells were counterstained with DAPI.

For hepcidin staining, cells were treated with infected, fixed and permeabilized as described above, and stained with 2µg/ml mouse anti-hepcidin antibody overnight at 4°C. Slides were imaged in a Zeiss Axiovert 200 M microscope at 40X and 63X and images acquired with Axiocam MRm grey scale camera.

Prussian blue for iron staining.  Four-hundred thousand THP-1 macrophages were grown and differentiated in eight well chamber microscopy slides as described above. After infection, cells were fixed with 4% formaldehyde in PBS for 10 minutes at room temperature, washed with PBS and stained twice with 4% HCl and 4% K4[Fe(CN)6] · 3H2O (1:1v/v) solution for 25 minutes (Prussian blue stain Kit Polysciences, Warrington, PA USA). After washing with PBS, cells were counterstained with filtered 1% Nuclear Fast red solution for five to 10 minutes. After gentle washing with PBS and double-distilled H2O, slides were mounted and imaged on an Axiovert 40CFL microscope. Images were acquired on a Axiocam MRC5 color camera with 20X and 40X lenses.

Intracellular labile iron pool (LIP) quantification.  Intracellular LIP was measured through a calcein quenching assay as previously described and adapted to flow cytometry analysis. Briefly, 3 × 10⁴ THP-1 macrophages were seeded in 48-well plates and treated with LPS or Pam3CSK4 (synthetic triacylated lipopeptide that activates the TLR2/TLR1 heterodimer) up to 48 hours in iron supplemented medium. At each timepoint, cells were washed twice with warm PBS, stained with calcein-AM (Invitrogen) for 15 minutes at room temperature, washed again with warm PBS, trypsinized, resuspended in FACS buffer and analyzed by flow cytometry before and after iron chelation with deferiprone (DFP). Quenched fluorescence was determined as percentage of Mean Fluorescence Intensity before iron chelation (xMFI) to 10 minutes after addition of DFP (xMFIyped) \( \left( \frac{xMFI_{yped}}{xMFI} \times 100 \right) \). Cells grown in non-iron supplemented medium were used as negative controls.

Image analysis.  Image analysis and mean pixel fluorescence intensity were determined with Zeiss Axiovision Rel 4.8.1 software. Colocalization and Prussian blue staining were quantified with imageJ 1.51 K software. Grey scale images were threshold for background and converted to binary files for automatic shape analysis. Bacilli–protein colocalization was determined as shapes with double positive pixels. Protein–protein colocalization was determined by double positive pixel areas.

Prussian blue staining was quantified in 200x color image thresholds for background and determined as percentage of blue pixel area over total pixel area averaged from at least four different fields from three independent experiments.

Statistics.  All data are presented as means ± SD. Statistical significance differences between two groups were determined using Student’s t test or 2-way ANOVA (Bonferroni) for multiple group comparison with GraphPad Prism software (CA, USA).

References
1. World Health Organization (WHO). Global tuberculosis report 2016 (2016).
2. Monack, D. M., Mueller, A. & Falkow, S. Persistent bacterial infections: the interface of the pathogen and the host immune system. Nat. Rev. Microbio. 2, 747–765 (2004).
3. Elmas, M. P., Giacomini, E., Severa, M. & Coccia, E. M. Pro-and anti-inflammatory cytokines in tuberculosis: A two-edged sword in TB pathogenesis. in Seminars in immunology 26, 543–551 (2014).
4. Goldberg, M. F., Saini, N. K. & Porcelli, S. A. In Mol. Genet. of Mycobacteria, Second Edition 747–772 (American Society of Microbiology, 2014).

5. Juffermans, N. P. et al. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J. Infect. Dis. 182, 902–8 (2000).

6. Meyer, D. Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload. Curr. Pharm. Des. 12, 1943–7 (2006).

7. Cronjé, L., Edmondson, N., Eisenach, K. D. & Bornman, L. Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions. FEMS Immun. & Med. Microbiol. 45, 103–112 (2005).

8. Boelaert, J. R., Vandecasteele, S. J., Appelberg, R. & Gordeuk, V. R. The effect of the host's iron status on tuberculosis. J. Infect. Dis. 195, 1745–53 (2007).

9. Olakanni, O., Schlesinger, L. S. & Brittigan, B. E. Hereditary hemochromatosis results in decreased iron acquisition and growth by Mycobacterium tuberculosis within macrophages. J. Leukocyte bio. 81, 195–204 (2007).

10. Shriver, Z., Capilla, I., Venkataraman, G. & Sasisekharan, R. In Heparin–A Century of Progress 159–176 (Springer, 2012).

11. Menozzi, F. D. et al. Identification of a heparin-binding hemagglutinin present in mycobacteria. J. Exp. Med. 184, 993–1001 (1996).

12. Pehe, K. et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412, 190–194 (2001).

13. Rashid, R. M., Lee, J. M., Fareed, J. & Young, M. R. I. In vivo heparran sulfate treatment alters the immune response of normal and LLC-bearing mice. Immunopharmacol Immunotoxicol 28, 67–79 (2006).

14. Conrad, H. E. Heparin-binding proteins. (Academic Press, 1997).

15. Killeen, R., Wait, R., Begum, S., Gray, E. & Mulloy, B. Identification of major heparin-binding proteins in plasma using electrophoresis and mass spectrometry. Int. J. Exp. Pathol. 85, (2004).

16. Cornet, A. D. Smith, E. G. M., Beishuizen, A. & Groeneveld, A. B. J. The role of heparin and allied compounds in the treatment of sepsis. Thromb. Haemost. 98, 579–86 (2007).

17. Attanasio, M. et al. Cytokine gene expression in human LPS- and IFNγ-stimulated mononuclear cells is inhibited by heparin. Thromb. Haemost. 79, 959–62 (1998).

18. Mu, E. et al. Heparin attenuates lipopolysaccharide-induced acute lung injury by inhibiting nitric oxide synthase and TGF-β1 Smad signaling pathway. Thromb. Res. 129, 479–485 (2012).

19. Xu, D. et al. Heparan sulfate modulates neutrophil and endothelial function in antibacterial innate immunity. Infect. immum 83, 3648–3656 (2015).

20. Ito, M. et al. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral research 7, 361–367 (1987).

21. Nahmis, A. J. & Kibrick, S. Inhibitory effect of heparin on herpes simplex virus. J. bacterial. 87, 1060–1066 (1964).

22. Poli, M. et al. Heparanase overexpression reduces hepcidin expression, affects iron homeostasis and alters the response to inflammation. PloS one 11, e0164183 (2016).

23. Poli, M. et al. Heparin: a potent inhibitor of heparin expression in vitro and in vivo. Blood 117, 997–1004 (2011).

24. Poli, M. et al. Glycol-split nonanticoagulant heparins are inhibitors of heparin expression in vitro and in vivo. Blood 123, 1564–73 (2014).

25. Rosett, W. & Hedges, G. R. Antimicrobial activity of heparin. J. Clin. Microbio. 11, 30–34 (1980).

26. Krishnan, N., Robertson, B. D. & Ilwa, G. Pathways of IL-1-β secretion by macrophages infected with clinical Mycobacterium tuberculosis strains. Tuberculosis (Edinb) 93, 538–47 (2013).

27. Sow, F. et al. Mycobacterium tuberculosis components stimulate production of the antimicrobial peptide hepcidin. Tuberculosis (Edinb) 91, 314–21 (2011).

28. Sow, F. B. et al. Role of STAT1, NF-κB, and C/EBPα in the macrophage transcriptional regulation of hepcidin by mycobacterial infection and IFNγ. J. Leukoc. Biol. 86, 1247–1259 (2009).

29. Wu, S. et al. Heparin Antinflammatory and Antimicrobial Activity of Heparin. Cytokine gene expression in human LPS- and IFNγ-stimulated mononuclear cells is inhibited by heparin. Thromb. Haemost. 79, 959–62 (1998).

30. Wu, S. et al. Lipopolysaccharide–induced mRNA expression of hepcidin in human peripheral blood leukocytes. Innate immunity 18, 318–324 (2012).

31. Liu, X.-B., Nguyen, N.-B. H., Marquess, K. D., Yang, F. & Haile, D. J. Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages. Blood Cells, Mol. Dis. 35, 47–56 (2005).

32. Nemeth, E. et al. Heparin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090–2093 (2004).

33. Zhang, L. et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol. Ther. 24, 398–405 (2016).

34. Bacon, B. R., Adams, P. C., Kowdley, K. V., Powell, L. W. & Tavill, A. S. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54, 328–43 (2011).

35. Adams, P. Epidemiology and diagnostic testing for hemochromatosis and iron overload. Int. J. Lab. hemat. 37, 25–30 (2015).

36. Poggiali, E., Cassigner, E., Zanaboni, L. & Cappellini, M. D. An update on iron chelation therapy. Blood Transfusion 10, 411 (2012).

37. Ramos, E. et al. Minhepcidins prevent iron overload in a hepcidin–deficient mouse model of severe hemochromatosis. Blood 120, 3829–3836 (2012).

38. World health organization (WHO) - tuberculosis. at http://www.who.int/immunization/diseases/tuberculosis/en/.

39. World Health Organization (WHO), Global tuberculosis report 2017 (2017).

40. Clemens, D. L. Characterization of the Mycobacterium tuberculosis phagosome. Trends in microbio. 4, 113–118 (1996).

41. Vergne, I., Chua, J., Singh, S. B. & Deretic, V. Cell biology of mycobacterium tuberculosis phagosome. Annu. Rev. Cell Dev. Biol. 20, 367–94 (2004).

42. Luo, M., Fadere, A. A. & Groves, J. T. Myocobacter-mediates iron acquisition within macrophages. Nat. Chem. Biol. 1, 149–53 (2005).

43. Macham, L. P., Ratledge, C. & Nocton, J. C. Extracellular iron acquisition by mycobacteria: role of the exochelins and evidence against the participation of mycobactin. Infect. Immun. 12, 1242–1251 (1975).

44. Srinathar, M. Iron homeostasis in Mycobacterium tuberculosis: mechanistic insights into siderophore-mediated iron uptake. J. Bacterial. 198, 2399–2409 (2006).

45. Madigan, C. A. et al. Lipidic discovery of deoxyxiderophores reveals a revised mycobactin biosynthesis pathway in Mycobacterium tuberculosis. Proc. Nat. Acad. Sci. 109, 1257–1262 (2012).

46. Rodriguez, G. M. Control of iron metabolism in Mycobacterium tuberculosis. Trends Microbial. 14, 320–7 (2006).

47. Wells, R. M. et al. Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PloS Pathog. 9, e1003120 (2013).

48. Surguladze, N., Patton, S., Cozzi, A., Fried, M. G. & Connor, J. R. Characterization of nuclear ferritin and mechanism of translocation. Biochem. J. 388, 731–40 (2005).

49. Gomes, M. S., Dom, G., Pedrosa, J., Boelaart, J. R. & Appelberg, R. Effects of iron depravation on Mycobacterium avium growth. Tuber. Lung Dis. 79, 321–8 (1999).

50. Chlota, S. et al. The iron efflux protein ferroportin regulates the intracellular growth of Salmonella enterica. Infect. Immun. 74, 3065–7 (2006).
51. Nairz, M. et al. Interferon-γ limits the availability of iron for intramacrophage Salmonella typhimurium. Eur. J. Immunol. 38, 1923–36 (2008).
52. Sia, J. K., Georgieva, M. & Rengarajan, J. Innate immune defenses in human tuberculosis: an overview of the interactions between Mycobacterium tuberculosis and innate immune cells. Journal of immunology research 2015 (2015).
53. Ernst, J. D. Macrophage receptors for Mycobacterium tuberculosis. Infec. Immun. 66, 1277–1281 (1998).
54. Himama, Z., Peña-Diaz, S., Joseph, S. & Av-Gay, Y. Immunoevasion and immunosuppression of the macrophage by Mycobacterium tuberculosis. Immunol. Rev. 264, 220–232 (2015).
55. Smith, J. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 16, 463–96 (2003).
56. Forrellad, M. A. et al. Virulence factors of the Mycobacterium tuberculosis complex. Virulence 4, 3–66 (2013).
57. Gordeuk, V., McLaren, C., MacPhail, A., Deichsel, G. & Bothwell, T. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachans 1929 thesis revisited. Blood 87, 3470–3476 (1996).
58. Gangaidzo, I. T. et al. Association of pulmonary tuberculosis with increased dietary iron. J. Infect. Dis. 184, 936–9 (2001).
59. Minchella, P. et al. Elevated hepcidin at HIV diagnosis is associated with incident tuberculosis in a retrospective cohort study. The Int. J Tuberc. Lung Dis. 18, 1337–1339 (2014).
60. Wisaksana, R. et al. Inverse relationship of serum hepcidin levels with CD4 cell counts in HIV-infected patients selected from an Indonesian prospective cohort study. PLoS One 8, e79904 (2013).
61. Kerkhoff, A. D. et al. Relationship between blood concentrations of hepcidin and anemia severity, mycobacterial burden, and mortality among patients with HIV-associated tuberculosis. The J. Inf. Dis. 213, 61–70 (2015).

Acknowledgements
We thank Dr. Tara Arvedson (Amgen Inc., CA, USA) for providing hepcidin and ferroportin monoclonal antibodies. We want to extend our sincere thanks to Dr. Russell Karls for his insight and thoughtful suggestions during this study. We also thank Shelly Helms for technical assistance in several parts of this project. This work was supported in part by an endowment from the University of Georgia Athletic Association (F. D. Q.) and Fulbright PhD Scholarship (R.A. 11/278).

Author Contributions
R.A. designed experiments, analyze data, prepared figures and wrote the manuscript; A.L. and L.E. performed experiments; F.Q. provided guidance, intellectual input, write the manuscript and reviewed the manuscript, P.G. designed research and experiments, analyze data, provided guidance, write the manuscript and reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-25480-y.

Competing Interests:
The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018